CLINICAL NEWS
Oral fluoroquinolones, one of the most commonly prescribed classes of antibiotics, may increase a person’s risk for developing a retinal detachment, according to a study published April 4 in JAMA. » More |
|
Zoster vaccine live (Zostavax, Merck) significantly reduced the risk of developing herpes zoster, or shingles, by nearly 70% in adults aged 50-59 compared with placebo, and it was reportedly well tolerated, according to a study published April 1 in Clinical Infectious Diseases. » More |
ADVERTISEMENT
New Drug Price PAC:
 Webinar
Predictive Acquisition Cost (PAC) tracks true drug acquisition cost more accurately and could replace AWP as the industry standard. Potentially high cost savings for health plans and their PBM’s.
View webinar |
|
Greater cost-sharing of asthma medications led to higher hospitalization rates in children 5 years or older, according to a new study. » More |
|
Certain antidepressants decrease depression in people with Parkinson’s disease without worsening their motor problems, according to a new study.» More |
|
A cluster of recently published articles might help policy-makers, patients, and providers decide when a high-cost treatment is “worth” the expense in terms of delivering better health to patients. » More |
EDITOR’S PICK
Coadministration of boceprevir with ritonavir-boosted HIV protease inhibitors could reduce drugs' effectiveness
FDA has notified healthcare professionals and patients that drug interactions between the hepatitis C virus protease inhibitor boceprevir (Victrelis, Merck) and certain ritonavir-boosted human immunodeficiency virus protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these drugs when they are used together. » Click here. |
CONTINUING EDUCATION
E-prescribing, a paperless, real-time transmission of data, places pharmacists squarely within the healthcare technology team.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login. |
FDA NEWS
FDA approved rotigotine transdermal system (Neupro, UCB) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson’s disease and as a treatment for moderate-to-severe primary restless legs syndrome. » More |
Survey
a) Aging US population
b) Expanded coverage via HC reform
c) Price inflation by drug manufacturers
d) Growth in the specialty drug market
e) Increased incidence of key chronic diseases (eg, diabetes, CAD, asthma/COPD, etc.)
Click here and see what your colleagues think, too.
Want to see the results of our last survey regarding Medicare's coverage policy of immunosuppressive therapy following kidney transplantation? Click here. |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
